These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6204036)

  • 21. High-performance liquid chromatography/tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasma.
    Sun Y; Sun J; Wen B; Shi S; Xu Y; Chen Y; Wang Y; Pan C; Zhang C; Zhang T; He Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):121-5. PubMed ID: 18571482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A radioimmunoassay for 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T; Mihara S; Repke DB; Moffatt JG
    Cancer Res; 1977 Feb; 37(2):619-24. PubMed ID: 832282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine and cytosine arabinoside in the treatment of murine brain tumor.
    Basler GA; Shapiro WR
    Cancer Treat Rep; 1976 Jul; 60(7):875-9. PubMed ID: 64295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The pharmacokinetic study on cytarabine nanoparticle lyophilization injection in rabbits].
    Zhou J; Jiang XH; He L; Li CR; Yang JY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):145-7. PubMed ID: 16468665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus.
    Webb TR; Mitsuya H; Broder S
    J Med Chem; 1988 Jul; 31(7):1475-9. PubMed ID: 2455053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Some cardiovascular effects of cyclocytidine.
    Herman EH; Chadwick DP
    Cancer Treat Rep; 1976 Nov; 60(11):1663-6. PubMed ID: 66094
    [No Abstract]   [Full Text] [Related]  

  • 27. Pilocarpine prodrugs. II. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters.
    Bundgaard H; Falch E; Larsen C; Mosher GL; Mikkelson TJ
    J Pharm Sci; 1986 Aug; 75(8):775-83. PubMed ID: 3772750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HPLC-MS/MS method for the simultaneous determination of MB07133 and its metabolites, cytarabine and arabinofuranosyluracil, in rat plasma.
    Wang D; Xiao Q; Yang W; Qian W; Yang J
    J Pharm Biomed Anal; 2016 Feb; 120():228-34. PubMed ID: 26760240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleosides. XCI. Some chemical properties of the antileukemic agent 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine.
    Fox JJ; Otter BA
    Ann N Y Acad Sci; 1975 Aug; 255():59-70. PubMed ID: 1059375
    [No Abstract]   [Full Text] [Related]  

  • 30. Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye.
    Assil KK; Weinreb RN
    Arch Ophthalmol; 1987 Mar; 105(3):400-3. PubMed ID: 3827719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in advanced colorectal carcinoma.
    Kemeny N; Yagoda A; Burchenal JH
    Cancer Treat Rep; 1978 Mar; 62(3):463-4. PubMed ID: 77190
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
    Yang JZ; Chen W; Borchardt RT
    J Pharmacol Exp Ther; 2002 Nov; 303(2):840-8. PubMed ID: 12388671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flavoxate and 3-methylflavone-8-carboxylic acid. Assay methods in blood and urine, plasma-red cells repartition and stability.
    Cova A; Setnikar I
    Arzneimittelforschung; 1975 Nov; 25(11):1707-9. PubMed ID: 1048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N4-(dialkylamino)methylene derivatives of 2'-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications.
    Kerr SG; Kalman TI
    J Pharm Sci; 1994 Apr; 83(4):582-6. PubMed ID: 8046619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclocytidine in breast cancer.
    O'Bryan RM; Baker L; Whitecar J; Salmon S; Vaughn C; Hoogstraten B
    Cancer Treat Rep; 1978 Mar; 62(3):455-6. PubMed ID: 77189
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanism of the cardiovascular actions of cyclocytidine.
    Burks TF; Loo TL; Grubb MN
    Proc Soc Exp Biol Med; 1978 Dec; 159(3):374-9. PubMed ID: 83653
    [No Abstract]   [Full Text] [Related]  

  • 37. Potential improvement in shelf life using the prodrug approach. II. A systematic examination of kinetic requirements.
    Nguyen NA; Notari RE
    Pharm Res; 1988 Oct; 5(10):634-8. PubMed ID: 3244615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers.
    Sarpietro MG; Ottimo S; Giuffrida MC; Rocco F; Ceruti M; Castelli F
    Int J Pharm; 2011 Mar; 406(1-2):69-77. PubMed ID: 21219999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility.
    Mahfouz NM; Hassan MA
    J Pharm Pharmacol; 2001 Jun; 53(6):841-8. PubMed ID: 11428660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and functional evaluation of a peptide derivative of 1-beta-D-arabinofuranosylcytosine.
    Balajthy Z; Aradi J; Kiss IT; Elödi P
    J Med Chem; 1992 Sep; 35(18):3344-9. PubMed ID: 1527783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.